Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...
In this video interview, Kimberly Tableman, founder & CEO, ESPERO, highlights how data standards are empowering the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback